Stockscreener 앱 받기
7.54
2.96%
-0.23
시간 외 거래:
7.54
전일 마감가:
$7.77
열려 있는:
$7.76
하루 거래량:
620.30K
Relative Volume:
1.38
시가총액:
$518.74M
수익:
-
순이익/손실:
$-153.16M
주가수익비율:
-2.0434
EPS:
-3.69
순현금흐름:
$-134.48M
1주 성능:
-14.22%
1개월 성능:
-3.21%
6개월 성능:
-52.93%
1년 성능:
-72.25%
1일 변동 폭
$7.54
$8.005
1주일 범위
$7.50
$8.80
52주 변동 폭
$6.85
$28.19
쿨리난 온콜로지 Stock (CGEM) Company Profile
명칭
Cullinan Therapeutics Inc
전화
617-410-4650
주소
ONE MAIN STREET, CAMBRIDGE
CGEM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
7.54 | 518.74M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
쿨리난 온콜로지 Stock (CGEM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-05-01 | 개시 | Stifel | Buy |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-06-15 | 개시 | TD Cowen | Outperform |
| 2022-11-21 | 개시 | BTIG Research | Buy |
| 2021-04-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 개시 | Evercore ISI | Outperform |
| 2021-02-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 개시 | SVB Leerink | Outperform |
| 2021-02-01 | 개시 | H.C. Wainwright | Buy |
모두보기
쿨리난 온콜로지 주식(CGEM)의 최신 뉴스
Cullinan Therapeutics Inc Reports Q1 2025 EPS Below Estimates wi - GuruFocus
Cullinan Therapeutics Reports Q1 2025 Financial Results - TipRanks
Cullinan Therapeutics: Q1 Earnings Snapshot - New Haven Register
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Cullinan Oncology (CGEM) Projects Financial Runway through 2028 | CGEM Stock News - GuruFocus
Cullinan Therapeutics (CGEM) Advances Autoimmune and Oncology Programs | CGEM Stock News - GuruFocus
MetLife Investment Management LLC Acquires 2,217 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Holdings Lifted by Wells Fargo & Company MN - Defense World
Invesco Ltd. Buys 1,395 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for CGEM - Defense World
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know - Yahoo Finance
Cullinan Therapeutics to begin US trial of CLN-978 for treating Sjögren’s disease - Yahoo
Barclays PLC Has $2.99 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Holdings Reduced by Legal & General Group Plc - Defense World
Cullinan Therapeutics to Initiate US Study of CLN-978 for Moderate to Severe Sjogren's Disease - marketscreener.com
Cullinan Therapeutics (CGEM) Begins Study of CLN-978 for Sjogren - GuruFocus
Cullinan Therapeutics to Initiate Study of CLN-978, a - GlobeNewswire
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Brokerages - Defense World
SEC Form DEF 14A filed by Cullinan Therapeutics Inc. - Quantisnow
Shareholders Can't Ignore US$502k Of Sales By Cullinan Therapeutics Insiders - simplywall.st
JPMorgan Chase & Co. Buys 169,104 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (CGEM) to Present Promising Lung Cancer St - GuruFocus
Cullinan Therapeutics to Present Results from REZILIENT1, a Phas - GuruFocus
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 - The Manila Times
Cullinan Therapeutics to Present Positive REZILIENT1 Study Results of Zipalertinib for NSCLC at 2025 ASCO Annual Meeting - Nasdaq
Why Acquire Shares Of Cullinan Therapeutics Inc (CGEM)? - Marketing Sentinel
Geode Capital Management LLC Acquires 6,220 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Federated Hermes Inc. Boosts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
HC Wainwright Reiterates “Buy” Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics receives EMA approval for rheumatoid arthritis drug trial - Yahoo
EMA greenlights Cullinan’s arthritis drug trial in Europe By Investing.com - Investing.com South Africa
Cullinan gets EU nod to begin testing CLN-978 in rheumatoid arthritis - Seeking Alpha
Cullinan Therapeutics Receives Approval from European Medicines - GuruFocus
Cullinan Therapeutics (CGEM) Receives EMA Approval for Rheumatoid Arthritis Trial | CGEM Stock News - GuruFocus
EMA greenlights Cullinan’s arthritis drug trial in Europe - Investing.com
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis - GlobeNewswire
Vanguard Group Inc. Reduces Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Wellington Management Group LLP Has $1.62 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
KLP Kapitalforvaltning AS Purchases Shares of 6,800 Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by American Century Companies Inc. - Defense World
Corebridge Financial Inc. Sells 1,941 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data - Seeking Alpha
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Analysts - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Swiss National Bank - Defense World
쿨리난 온콜로지 (CGEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.15%
자본화:
|
볼륨(24시간):